The gender disparity observed in the incidence of hepatocellular carcinoma (HCC) suggests an important role of estrogens in HCC pathogenesis. In this study, we conducted a case-control study to investigate whether breast cancer riskassociated single nucleotide polymorphisms (SNPs) located at estrogens loci identified by genome-wide association studies (GWASs) also predispose to HCC in a Chinese population. Three candidate SNPs at 6q25.1 were genotyped in 2025 HCC cases and 2032 healthy controls. Differential expression analyses and expression quantitative trait loci (eQTL) analyses were conducted to further explore the potential function of significant SNPs and genes they reside in. Two of the three candidate SNPs (rs9383951 and rs9485372) were observed to be significantly associated with HCC risk. Under a dominant model, the odds ratios (OR) for rs9383951 and rs9485372 were 1.28 (95% CI: 1.10-1.49, P = 0.002) and 1.34 (95% CI: 1.17-1.53, P = 2.75 × 10 -5 ), respectively. We also found a significant accumulative effect of these two SNPs and there was a gradual increase in OR with a greater number of hazard genotypes. Moreover, the association between rs9383951 and HCC risk was specific in males. Lower ESR1 and TAB2 expressions were investigated in hepatic tumor tissues than adjacent normal tissues. We found a significant association between rs9383951 and ESR1 expression (P = 0.047). Besides, ESR1 expression was significantly correlated with the expression of TAB2. Taken together, our study identified two genetic variants at 6q25.1 newly associated with HCC risk, suggesting ESR1 and estrogen signaling may play a role in mediating susceptibility to HCC in Chinese population.
Introduction
Hepatocellular cancer (HCC) is the most frequent primary liver malignancy and one of the most lethal cancers around the world. More than 782 thousands new liver cancer cases and 745 thousands deaths recorded worldwide during 2012 (1) . Approximately 80% of HCC occur in less developed countries. Of particular importance, China alone accounts for about 50% of the total number of global cancer cases and deaths (2) . Owing to its limited early disease-specific signs and symptoms, HCC usually diagnosed at a late stage of the disease, resulting in a poor prognosis (3) . Therefore, identification of biomarkers associated with the risk of HCC would allow better screening of high-risk populations and thus beneficial for HCC prevention and treatment.
The pathogenesis of HCC is a multistage process with the complex interactions of various risk factors including infection with hepatitis B virus (HBV) and/or hepatitis C virus, alcohol consumption, cirrhosis, aflatoxin intake and multiple genetic variants (4, 5) . Although many signaling pathways have been implicated in HCC, the molecular basis of HCC remains largely unknown. Intriguingly, there is a male predilection in HCC, with significantly higher incidence in males than females (6) . This male predominance is further supported by the clinical observations that chronic liver disease progresses more rapidly to cirrhosis in males than females. Therefore, HCC developed from cirrhosis is largely considered to be the disease of men and postmenopausal women (7) . A similar male predominance is also seen in rodent HCC models (8, 9) . In view of this remarkable sexual dimorphism, growing evidences conducted in vitro and in vivo have been initiated to explore the importance of sex hormones in HCC development. Administration of estrogens to male mice inhibits development of chemically induced HCC (10, 11) , while ovariectomized female mice develop more liver tumors than normal mice and female mice deficient for the estrogen receptor alpha (ERα) lose their resistance to HCC (12, 13) . These evidences suggest that estrogens may be the drivers of sexual dimorphism in HCC, though the mechanisms that render this disparity and the anticarcinogenic activity of estrogens are ambiguous.
As we know, estrogens play a major role in breast cancer pathogenesis according to their pronounced effects on female reproductive system (14) . It is conceivable that estrogens-related risk factors for breast cancer may also impinge on HCC susceptibility. In fact, genetic polymorphism in ESR1 (estrogen receptor α) has been reported may play a role in mediating susceptibility to HCC in Chinese hepatitis B virus carriers (15) . Genome-wide association studies (GWAS) of breast cancer have identified several susceptibility loci located in genes regulating estrogen signaling. For example, SNP rs2046210 at 6q25.1, located upstream of the gene ESR1, was firstly reported in strong association with breast cancer among Chinese women (16) . We conjectured that these cancer related SNPs at estrogen related loci identified by GWAS may be also associated with HCC risk and may contribute to the gender disparity of this type of cancer. In order to test this hypothesis, we performed a hospital-based case-control study to investigate the role of estrogen related polymorphisms identified by breast cancer GWAS in the risk of HCC in a Chinese Han population.
Materials and methods

Study subjects and tissue samples
A total of 2025 HCC cases and 2032 healthy controls were recruited in this study. For SNPs with minor allele frequency of 0.10, we calculated that, to detect an odds ratio (OR) of 1.5, the power of our sample size reaches 0.986. HCC cases were recruited between March 2009 and December 2012 from two hospitals: the Cancer Institute and Hospital in Beijing, China and the Tongji Hospital of Huazhong University of Science and Technology in Wuhan, China. Controls were randomly selected from health physical examination persons in the same hospital during the same period as HCC patients enrolled, part of which were also included in our previous studies (17, 18) . All these participants were unrelated Han Chinese. The selection criteria for cases included newly diagnosed and histopathologically confirmed HCC, without previous radiotherapy or chemotherapy, but no restriction in gender, age or disease stage. All controls were cancer-free and HBV free individuals with frequency matched to cases by gender and age (±5 years). The characteristics for each participant including sex, age, smoking and drinking habits were collected by medical records. In addition, 2 ml of peripheral venous blood sample was obtained from each subject. HBV-induced HCC or non-HBV-induced HCC were judged by the HBV infection status in HCC cases. A total of 85 normal hepatic tissue samples were acquired from 85 HCC patients who received a surgical treatment in the Peking Union Medical College Hospital, Beijing, China. All tissues were removed from the normal hepatic tissues with a distance at least 5 cm away from the hepatic tumors. These samples were snap-frozen in liquid nitrogen as soon as possible and stored at −80°C. Additionally, blood samples were also obtained from these subjects. At recruitment, all participants provided written informed consent, and the study protocol was approved by the institutional review board of Tongji Medical College, Huazhong University of Science and Technology.
Selection of candidate SNPs
Polymorphisms were selected as a candidate SNP if it meets the following two criteria: (1) breast cancer associated genetic variant which identified by GWAS in Chinese or East Asian population, (2) located in estrogen related loci. On the basis of previous published GWAS (16, 19) , we finally selected three breast cancer-associated SNPs as candidate SNPs in our study. These three SNPs, rs9383951, rs2046210 and rs9485372, are located at chromosome 6q25.1, in which region the estrogen receptor 1 (ESR1) gene is located. ESR1 encodes an estrogen receptor and has been documented to play a pivotal role in breast cancer development and progression. SNP rs9383951 is located in intron 5 of the ESR1 gene. SNP rs2046210 is located in an intergenic region 29 kb upstream of the ESR1 gene. SNP rs9485372 is located in intron 2 of the TGF-beta activated kinase 1/MAP3K7 binding protein 2 (TAB2) gene. However, since located approximately 2.5 Mb from ESR1 gene, this SNP may also work mediated through regulating the ESR1 gene.
DNA extracting and genotyping
Genomic DNAs were extracted from the peripheral blood samples of all subjects using the RelaxGene Blood System DP319-02 (Tiangen, Beijing, China) according to the manufacturer's instructions. All SNPs were genotyped by the TaqMan SNP Genotyping Assay (Applied Biosystems, Foster city, CA) using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster city, CA). Genotyping was performed without knowledge of case or control status of the subjects. Quality control was further monitored by including 5% duplicate samples, with the 100% concurrence rate of the duplicate sets. Data analyses were achieved by Sequencing Detection System version 2.4.1. The three candidate SNPs included in this study had an average genotyping call rate of 98.0% and all the SNPs were genotyped with call rates more than 97.4%.
Comparison of gene expression in hepatic normal and tumor tissues
To investigate the difference of gene expression levels in hepatic tumor and normal tissues, ESR1 and TAB2 mRNA expression data of 50 paired HCC tumor tissues and adjacent normal tissues were downloaded from The Cancer Genome Atlas (TCGA) dataset. To further detect the co-expression of these two genes, expression data of 324 tumor tissues were additionally downloaded. All raw expression data were standardized by DESeq package (20) . And the standardized expression of ESR1 and TAB2 were then compared between normal hepatic and tumor tissues, respectively.
Expression quantitative trait loci (eQTL) analyses
DNA extraction and genotyping of rs9383951 and rs9485372 were performed as described above. Total RNAs were extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNAs Abbreviations eQTL expression quantitative trait loci GWAS genome-wide association studies HBV hepatitis B virus HCC hepatocellular carcinoma SNP single nucleotide polymorphism were reversetranscribed into cDNA using PrimeScript™ RT Master Mix (TaKaRa Bio, Tokyo, Japan). Real-time quantitative reverse transcription PCR (qRT-PCR) was carried out with a SYBR TM Green Master Mix (Applied Biosystems) using the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster city, CA). We measured the mRNA expression levels of two genes (ESR1 and TAB2) which significant SNPs located in. Primers for the different genes amplified are presented in Supplementary  Table 1 , available at Carcinogenesis Online. All reactions were done in duplicates, and GAPDH was used as an endogenous control. The relative expression levels were calculated using the 2 −ΔCt method. However, all original expression data were standardized with logarithmic transformation. To validate the results of our study, we also downloaded the genotype information about rs9383951 and rs9485372 from TCGA dataset and performed eQTL analyses with the expression data downloaded before.
Statistical analyses
The Hardy-Weinberg equilibrium for each candidate variant was assessed by a goodness-of-fit χ 2 test in the control group. Unpaired t test or Pearson χ 2 test was used to assess differences in distribution of demographic characteristics and genotypes between cases and controls. To estimate the effects of each polymorphism on HCC risk, the odds ratios (OR) and 95% confidence intervals (CI) were calculated by unconditional multivariate logistic regression analysis with adjustment for gender, age, smoking and drinking status. Dominant, recessive and additive genetic models were assumed in the association analyses. The Cochran-Armitage trend test was applied to estimate the trend of relationship. Potential interaction between significant SNPs was systematically investigated by a pair-wise analysis under a multiplicative interaction model. And the accumulative effect of significant SNPs was also calculated by counting the number of risk alleles in each participant. In addition, stratified analyses were performed to evaluate whether gender or other different demographic characteristics have impacts on the relationship between genetic variants and HCC susceptibility. We compared the mRNA expression levels of ESR1 and TAB2, respectively, between tumor and peritumor tissues using paired student t test. The co-expression correlation of ESR1 and TAB2 was evaluated by Pearson correlation and linear regression analysis. Expression quantitative trait loci analyses were performed by comparing the gene expression levels among different genotypes using unpaired t test.
All statistical analyses were performed with SPSS 13.0 (IBM Corporation, Armonk, NY, USA) and all P values were two sided with P < 0.05 considered significant.
Results
Characteristics of study subjects
There were 2025 HCC cases and 2032 frequency-matched healthy controls in our study, with males account for a percentage of 79.6%. More than 75% HCC cases were infected with HBV. No significant differences were found between cases and controls in distribution of sex and age. However, rates of smoking and drinking were significantly higher in cases than controls. In contrast with non-smokers, the OR for smokers was 1.14 (95% CI: 1.01-1.29, P = 0.037). Drinking was also significantly associated with increased HCC risk, with a moderate OR of 1.14 (95% CI: 1.00-1.29, P = 0.045, data not shown). The detailed information about study subjects are shown in Table 1 .
Association of candidate SNPs and HCC risks
None of the candidate SNPs was deviated from Hardy-Weinberg equilibrium in control group, thus all included in our association analyses ( Table 2 ). The associations between these SNPs and HCC risk were shown in Table 3 . Among the three SNPs, two SNPs (rs9383951 and rs9485372) were observed to be significantly associated with HCC risk by adjustment of age, sex, smoking and drinking status. The associations between rs9383951 and HCC risk were consistently significant under heterozygous model, dominant model and additive model. Individuals carrying rs9383951 GC or CC genotype showed a significantly elevated risk of HCC when compared to individuals with the wild TT genotype (OR: 1.27, 95 % CI: 1.08-1.48, P = 0.003). Since the low frequency of variant homozygote for rs9383951, we failed to estimate the significant association under homozygous and recessive model. The effects of rs9485372 on HCC risk were significant and robust in different genetic models. Significant dosage effect was observed between rs9485372 A allele and HCC risk: the risk for HCC increase 21% (OR = 1.21, 95% CI: 1.11-1.33, P = 2.65 × 10 -5 ) with per one A allele increment. No significant association was observed for the other one SNP rs2046210.
Since the two significant SNPs, rs9383951 and rs9485372, were physically adjacent on chromosome location, we estimated the interaction and accumulative effect of these two SNPs. There ) with per one risk allele increment. Specifically, compared with individuals carrying no hazard genotypes, individuals carrying one and more than one hazard genotypes had an adjusted OR of 1.32 (95% CI: 1.12-1.54, P = 0.001) and 1.51 (95% CI: 1.27-1.80, P = 2.86 × 10 -6 ), respectively.
Stratified analyses
To illustrate whether the effects of these SNPs were different between males and females, we conducted a stratified analysis according to sex. Significant associations were observed both in males and females for rs9485372 (Figure 1) . In a dominant model, the ORs for males and females were 1.26 (95% CI: 1.08-1.47, P = 0.003) and 1.68 (95% CI: 1.24-2.28, P = 0.001), respectively. However, the association of rs9383951 and HCC risk was male-specific. Compared with the GG genotype, the OR for the GA or AA genotype was 1.28 (95% CI: 1.08-1.52, P = 0.005) in males, while in females the effect was non-significant (OR = 1.29, 95% CI: 0.90-1.83, P = 0.164). In consistent with the results of combined analysis, we found no significant association between rs2046210 and HCC risk no matter in males or in females.
To further investigate the impact of other demographic characteristics on the relationship between SNP and HCC risk, we conducted stratified analyses by HBV infection, smoking and drinking status, respectively ( Table 3 ). The associations were consistent between HBV positive and HBV negative HCC. As for smoking, significant associations were observed both in smokers and non-smokers for rs9485372. However, rs9383951 was significantly associated with HCC risk in non-smokers, but showed a marginal effect in smokers. As for drinking, the association of rs9485372 and HCC risk was only significant in non-drinkers but not in drinkers. Compared with people carry the wild GG genotype, the OR for people carry the GA or AA risk genotype was 1.51 (95% CI: 1.26-1.81, P = 9.05 × 10 -6 ) for non-drinkers and 1.14 (95% CI: 0.93-1.41, P = 0.216) for drinkers. The rs9383951 was significantly associated with HCC risk in drinkers (OR = 1.32, 95% CI: 1.03-1.67, P = 0.026) but showed a marginal effect in non-drinkers (OR = 1.20, 95% CI: 0.98-1.48, P = 0.077).
Differential gene expression analysis
Considering the conspicuous genetic lesions of ESR1 variation rs9383951 in HCC, we next evaluated the ESR1 expression in HCC tumor tissues and adjacent normal tissues using data downloaded from TCGA database. Lower ESR1 expression was observed in hepatic tumor than normal tissues. The fold change of tumor to normal tissues reached as low as 0.25 ( Figure 2A , P < 0.001). We also compared the expression of the other significant gene TAB2 between tumor and peritumor tissues. In accordance with ESR1, the expression level of TAB2 was significantly lower in tumors comparing with its expression in normal tissues. The fold change of tumor to normal tissues was 0.72 ( Figure 2B , P < 0.001). Besides, ESR1 expression correlated positively with the expression of TAB2 (r = 0.53, P < 0.001, Figure 2C ), suggesting a co-expression relationship between these two closely adjacent genes.
eQTL analysis using normal expression data
To explore whether the significant genetic variants can affect local gene expressions in an allele specific manner, we conducted eQTL analyses with the use of genotyping and expression data from 85 normal hepatic tissue samples. In accordance with the results of TCGA dataset, we found a co-expression relationship between ESR1 and TAB2 (r = 0.71, P < 0.001, Figure 3A) . As expected, SNP rs9383951 was significantly correlated with ESR1 gene expression. People who carry the GC genotype had a decreased expression level of ESR1 gene compared to people who carry the GG genotype ( Figure 3B , P = 0.047). The correlation of rs9485372 and TAB2 expression reached a borderline significance ( Figure 3C ). Since the male-specific effect of rs9383951 on HCC risk, we next evaluate the relationship between this variant and ESR1 expression in males and females respectively. Compared to people carry the wild GG genotype, people who carry the risk genotype GC had lower ESR1 expression in both males and females (Supplementary Figure 2, available at Carcinogenesis Online). However, there was no significant statistical difference between GG and GC genotype no matter in males or in females, owing to the low frequency of this variation and the limited sample size of each subgroup. Using the expression data from 50 normal tissue samples in TCGA dataset, we also found decreased expression of ESR1 and TAB2 among people who carry the risk genotypes compared to wild genotypes (Supplementary Figure 3 , available at Carcinogenesis Online). However, the differences were not statistically significant maybe due to the ethnic heterogeneity or limited sample size.
Discussion
HCC remains a significant disease worldwide. The striking gender predilection in HCC incidence suggests an important role of sex hormones in HCC pathogenesis. The current study provides limited but suggestive evidence of a relationship among variants at 6q25.1 and risk of HCC. We observed differential expressions of ESR1 and TAB2 between HCC tumor cells and adjacent normal liver cells. Furthermore, the significant SNP rs9383951 was significantly associated with expression of ESR1 in an allelespecific manner. These findings highlight the significance of estrogen in the context of liver carcinogenesis and may help to explain the observed gender disparity in HCC development.
Liver is the major site of estrogen metabolism. Alterations in the metabolism of estrogen are considered a critical factor in the process of liver carcinogenesis and the physiologic differences between males and females may drive the gender disparity of HCC incidence (21) . One previous study proposed that estrogenmediated inhibition of IL-6 production reduced liver cancer risk in females, confirming the importance of estrogen signaling in HCC initiation (13) . The human ESR1 gene is located on chromosome 6 at 6q25.1 and encodes an estrogen receptor ERα. As a ligand-activated transcription factor, ERα is important for activation of numerous genes with different functions in maintaining cellular homeostasis. These transcriptional regulations are achieved through interaction with estrogen responsive element sequences in specific target genes or through protein-protein interactions with other transcription factors (22) . Low expression of ESR1 in liver cancer tissues suggests a pivotal role of ERα in hepatic tumor occurrence and development. Genetic variants in the ESR1 gene have been reported to alter ERα expression and modulate downstream signaling, thus affecting susceptibility of complex diseases (23, 24) . In this study, we found two SNPs which located on 6q25.1, rs9383951 and rs9485372, were significantly associated with HCC risk. Gender-specific analyses showed that the relationship of rs9383951 and HCC risk was driven by significant association observed in men. Coincidentally, a sodium intervention study also identified male-specific association between ESR1 rs9383951 and salt sensitivity of blood pressure (25) . Moreover, male-specific associations of ESR1 variants have also been reported for cardiovascular diseases (26, 27) . We also observed that the GC risk genotype of rs9383951 was associated with a significantly decreased expression level of the ESR1 gene. Although rs9383951 locates in an intron region of ESR1 gene, this variant resides in binding sites of SETDB1 (SET domain, bifurcated 1) and GATA2 (GATA binding protein 2) transcription factors (28). SETDB1 is a histone methyltransferase which mediating biological effect mainly through gene silencing and transcriptional repression. This gene was proved to be an oncogene that is frequently up-regulated in human HCC and the over-expressed SETDB1 can regulate liver cancer cell growth and promote cancer metastasis (29, 30) . GATA2 is a zinc-finger transcription factor which plays an essential role in regulating transcription of genes involved in cell development and proliferation. Perturbations in GATA2 network were also found in diverse cancers, including lung cancer, prostate cancer, leukemia and HCC (31) (32) (33) (34) . We propose that rs9383951 risk allele may facilitate HCC development via regulating ESR1 expression with mediation of transcription factors mentioned above. The correlations of rs9485372 and HCC risk were firm and consistent both in males and females. SNP rs9485372 is located in intron 2 of the TAB2 gene and approximately 2.5 Mb from ESR1 gene. Given the pivotal role of TAB2 gene in TGF-β pathway and their contribution to the development of cancer (35) , it is possible that the association between rs9485372 and HCC risk may be mediated through the TGF-β signaling pathway. However, this variant seemed to have no significant correlation with expression level of TAB2 in our study. So it is also possible that the association may be mediated by regulating the estrogen signaling, considering the cumulative effect of the two significant SNPs and the co-expression of TAB2 and ESR1 revealed in our study. In fact, several other open reading frames in the 6q25.1 region were shown to be co-expressed with ESR1 (36) . The function of co-expressed genes may be important for interpretating the relationship between SNPs in this region and HCC risk. Unlike the consistent associations between rs9383951 and HCC risks in drinkers and non-drinkers, the association of rs9485372 and HCC risk was only significant in non-drinkers but not in drinkers. This result suggests that rs9485372 may exhibit a cancer promotion effect in non-alcoholic HCC. It seems that the two significant SNPs have both connections and differences, and the putative functions of these two SNPs are still waiting revealed. Further studies are needed to shed light on the underlying mechanisms of rs9383951 and rs9485372 in HCC pathogenesis.
Several studies previously reported convincing associations of SNP rs2046210, located upstream of the ESR1 gene, with breast cancer risk across different populations (16, 37, 38) . Unexpectedly, no significant association of this variant with HCC was found in our study, no matter in males or in females. Considering the compelling effects of rs2046210 on breast cancer susceptibility, attempts have been made to illustrate the potential function of rs2046210 and SNPs in strong linkage disequilibrium with it. Fine-mapping and functional analyses provided little support for the modulation of rs2046210 locus on ESR1 gene. Using RNA sequencing (RNA-seq) data from TCGA dataset, a study recently reported allelic imbalance in ESR1 expression among heterozygotes for proxy SNPs of rs2046210 (39) . Sun and her colleagues investigated the expression levels of nine genes flanking a 1 Mb region around SNP rs2046210 in breast cancer tissues and adjacent normal tissues and found that the association between rs2046210 and breast cancer risk may be mediated through SNPs regulating expression of the AKAP12 gene (40) . An evaluation of functional genetic variants at 6q25.1 showed that SNP rs9383935 which was in strong linkage disequilibrium with rs2046210 might alter the binding capacity of miR-27a to the 3′untranslated region (3′UTR) sequence of coiled-coil domain containing 170 (CCDC170, also called C6orf97) and consequently influence this gene expression (41) . Hence, it is not conclusive whether the genetic effects of rs2046210 concerned with ER signaling. SNP rs2046210 may be a susceptibility locus specific for breast cancer and thus play little role in HCC carcinogenesis. However, further research into the function of rs2046210 and its potential association with HCC may be warranted.
Certain limitations should be addressed. First, only three GWAS reported SNPs were included in this study. Comprehensive approaches are required to systematically elaborate the role of sex hormone related variants in HCC development. Second, the selected SNPs in our study are tagging SNPs with unclear functions. The frequencies of rs9383951 and rs9485372 were distinct across different populations. For example, the frequency of rs9485372 in Asians (0.423) was much higher than its frequency in other populations (0.205 in Africans, 0.192 in Americans and 0.164 in Europeans). It is unclear whether our findings are Chinese Han population-specific or common in other populations. Therefore, replication efforts in diverse populations will be necessary to confirm our findings in the future. Fine-mapping studies are also needed to identify those causal variants functioned in HCC development. Besides, underling mechanisms of significant SNPs and the precise role of estrogen and the significance of their receptors in HCC still remain poorly understood. Further studies of possible mechanisms are warranted.
In conclusion, we identified two genetic variants at 6q25.1 newly associated with HCC risk, including rs9383951 in ESR1 and rs9485372 in TAB2. The current study provides additional insights into the genetics and etiology of HCC and may help us to better understand the biology contributing to the sex disparity in HCC. Further studies are needed to clarify the causal variants and shed light on the underlying mechanisms in HCC pathogenesis.
